Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of Chicago
With
PRIMARY OBJECTIVES: I. To compare steady state pharmacokinetics (PK) (primarily minimum concentration \[Cmin\], maximum concentration \[Cmax\], and area under the curve \[AUC\]) of celecoxib on day 7 of monotherapy versus on day 14 of concomitant administration with capecitabine. SECONDARY OBJECTIVES: I. To develop a celecoxib PK drug interaction model using longitudinal data and determine whether the results are concordant with results from the primary objective. II. To assess the impact of known cytochrome P450 2C9 (CYP2C9) pharmacogenetic variants with reduced enzyme activity (CYP2C9\*2 and \*3) on the between subject variability in celecoxib PK. III. To assess tumor response by the Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) and explore whether there is any correlation between celecoxib PK and response. IV. To assess toxicity by the Common Terminology Criteria for Adverse Events (CTCAE, version 4.0) and explore whether there is any correlation between celecoxib PK and toxicities related to either celecoxib or capecitabine. OUTLINE: Patients receive celecoxib orally (PO) twice daily (BID) for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
